Prognostic Value of Serum Uric Acid in Patients on the Waiting List before and after Renal Transplantation

Carregando...
Imagem de Miniatura
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2015
Editora
HINDAWI LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
INTERNATIONAL JOURNAL OF NEPHROLOGY, article ID 375606, 6p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. High serumuric acid (UA) is associated with increased cardiovascular (CV) risk in the general population. The impact of UA on CV events and mortality in CKD is unclear. Objective. To assess the relationship between UA and prognosis in hemodialysis (HD) patients before and after renal transplantation (TX). Methods. 1020 HD patients assessed for CV risk and followed from the time of inception until CV event, death, or TX (HD) or date of TX, CV event, death, or return to dialysis (TX). Results. 821 patients remained on HD while 199 underwent TX. High UA (>= 428 mmol/L) was not associated with either composite CV events or mortality in HD patients. In TX patients high UA predicted an increased risk of events (P = 0.03, HR 1.6, and 95% CI 1.03-2.54) but not with death. In the Cox proportional model UA was no longer significantly associated with CV events. Instead, a reduced GFR (<50 mL/min) emerged as the independent risk factor for events (P = 0.02, HR 1.79, and % CI 1.07-3.21). Conclusion. In recipients of TX an increased posttransplant UA is related to higher probability of major CV events but this association probably caused concurrent reduction in GFR.
Palavras-chave
Referências
  1. Chonchol M, 2007, AM J KIDNEY DIS, V50, P239, DOI 10.1053/j.ajkd.2007.05.013
  2. Culleton BF, 1999, ANN INTERN MED, V131, P7
  3. Fang J, 2000, JAMA-J AM MED ASSOC, V283, P2404, DOI 10.1001/jama.283.18.2404
  4. Gerhardt U, 1999, CLIN TRANSPLANT, V13, P375, DOI 10.1034/j.1399-0012.1999.130502.x
  5. Haririan A, 2010, TRANSPLANTATION, V89, P573, DOI 10.1097/TP.0b013e3181c73c18
  6. Hoieggen A, 2004, KIDNEY INT, V65, P1041, DOI 10.1111/j.1523-1755.2004.00484.x
  7. Hozawa A, 2006, ATHEROSCLEROSIS, V187, P401, DOI 10.1016/j.atherosclerosis.2005.09.020
  8. Hsu SP, 2004, NEPHROL DIAL TRANSPL, V19, P457, DOI 10.1093/ndt/gfg563
  9. Johnson RJ, 2003, HYPERTENSION, V41, P1183, DOI 10.1161/01.HYP.0000069700.62727.C5
  10. Kanbay M, 2005, TRANSPLANT P, V37, P3119, DOI 10.1016/j.transproceed.2005.08.042
  11. Lee SMK, 2009, AM J NEPHROL, V29, P79, DOI 10.1159/000151292
  12. Liu WC, 2012, CLIN J AM SOC NEPHRO, V7, P541, DOI 10.2215/CJN.09420911
  13. Madero M, 2009, AM J KIDNEY DIS, V53, P796, DOI 10.1053/j.ajkd.2008.12.021
  14. Mazzali M, 2005, SEMIN NEPHROL, V25, P50, DOI 10.1016/j.semnephrol.2004.09.008
  15. Meier-Kriesche HU, 2009, CLIN J AM SOC NEPHRO, V4, P1655, DOI 10.2215/CJN.02700409
  16. Navaneethan SD, 2009, NEPHROL DIAL TRANSPL, V24, P1260, DOI 10.1093/ndt/gfn621
  17. Santos RD, 2007, AM J CARDIOL, V99, P42, DOI 10.1016/j.amjcard.2006.07.057
  18. Suliman ME, 2006, AM J KIDNEY DIS, V48, P761, DOI 10.1053/j.ajkd.2006.08.019
  19. Viazzi F, 2005, HYPERTENSION, V45, P991, DOI 10.1161/01.HYP.0000161184.10873.ea